Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
New method spots signs of Earth's primordial life in ancient rocks - 2Grasping the Qualifications Among Separation and Dissolution
- 3How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- 4Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness
- 5Turning to turkey’s tryptophan to boost mood? Not so fast
- How Skoda Lost Its Biggest Market In Just Seven Years
- Dominating the Mastercard Endorsement Cycle: Six Fundamental Stages
- Figure out How to Pick a Crematorium: Key Contemplations.
- 10 Hints for a Fruitful New employee screening
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- At least 490 protesters killed in Iran, activists say
- 2 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- NASA unveils close-up pictures of the comet popping by from another star
